RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy

Journal article

Peer reviewed

A. B Schwartz, S. B Kahn, B Kelch, K. E Kim and E Pequignot

Clinical nephrology, v 38(5)

1992

PMID: 1451342

Additional Links

Biological and medical sciences

Blood. Blood coagulation. Reticuloendothelial system

Medical sciences

Pharmacology. Drug treatments

9 Record Views

Title: RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy
Creators: A. B Schwartz - Hahnemann univ., dep. medicine, Philadelphia PA 19102-1192, United States
S. B Kahn - Hahnemann univ., dep. medicine, Philadelphia PA 19102-1192, United States
B Kelch - Hahnemann univ., dep. medicine, Philadelphia PA 19102-1192, United States
K. E Kim - Hahnemann univ., dep. medicine, Philadelphia PA 19102-1192, United States
E Pequignot - Hahnemann univ., dep. medicine, Philadelphia PA 19102-1192, United States
Publication Details: Clinical nephrology, v 38(5)
Publisher: Dustri
Resource Type: Journal article
Language: English
Academic Unit: Nephrology (and Hypertension)
Web of Science ID: WOS:A1992JZ06900007
Scopus ID: 2-s2.0-0026495177
Other Identifier: 991019350593704721

This publication has contributed to the advancement of the following goals:

Data related to this publication, from InCites Benchmarking & Analytics tool: